Antilipolytic activity of viprostol, a transdermally active antihypertensive PGE2 analog
| Autor: | David L. Crandall, Barbara A. Davis, Peter Cervoni, Florence H. Lizzo, Vanessa Vu |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Glycerol
Male Prostaglandins E Synthetic medicine.medical_specialty Epinephrine Lipolysis medicine.medical_treatment Alpha (ethology) In Vitro Techniques Biology Biochemistry Dinoprostone chemistry.chemical_compound Endocrinology 1-Methyl-3-isobutylxanthine Internal medicine Adipocyte medicine Animals Obesity Prostaglandin E2 Antihypertensive Agents Rats Inbred Strains Metabolism In vitro Rats Kinetics Adipose Tissue chemistry lipids (amino acids peptides and proteins) medicine.drug Prostaglandin E |
| Zdroj: | Prostaglandins. 33:767-773 |
| ISSN: | 0090-6980 |
| DOI: | 10.1016/0090-6980(87)90042-6 |
| Popis: | Viprostol, a novel prostaglandin E2 congener, was assessed for in vitro antilipolytic activity in the spontaneously obese rat. In isolated epididymal adipocytes, viprostol exhibited a dose-dependent inhibition of catecholamine-stimulated lipolysis at concentrations ranging from 10 microM to 1 mM, but was ineffective at lower concentrations. Additionally, viprostol exhibited approximately 50% of the antilipolytic activity of naturally-occurring PGE1 and PGE2 at similar concentrations, but was as potent as PGF2 alpha. At 10 microM, viprostol inhibited maximum catecholamine-stimulated lipolysis by approximately 35% of the total, hormone-stimulated glycerol release. The results of these experiments indicate that viprostol exhibits antilipolytic activity in vitro, but is less potent than the naturally-occurring PGE's to which it is most closely related structurally. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|